Thanks Southoz.
Luckily the differentiation of TPM driven Diclofenac is that it has the capabilities to bypass the systemic system, which in fact helps to minimise those side effects that are recognised, mainly with oral Diclofenac.
This is where we will have the capabilities to supercede existing Diclofenac products.
Going prescription/FDA at the time of initial trials was likely to be resisted due to financial limitations, IMO, of course.
boost for global diclofenac gel market, page-6
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.2¢ | $11.50K | 4.335M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 63 | 101422109 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 20872825 | 7 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |